Larimar Therapeutics, Inc.
LRMR
$4.36
$0.092.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 5.90% | 27.68% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.39% | -51.39% | |||
| Operating Income | -10.39% | 51.39% | |||
| Income Before Tax | -10.70% | 52.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -10.70% | 52.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.70% | 52.62% | |||
| EBIT | -10.39% | 51.39% | |||
| EBITDA | -10.42% | 51.43% | |||
| EPS Basic | 4.27% | 55.28% | |||
| Normalized Basic EPS | 4.29% | 55.28% | |||
| EPS Diluted | 4.27% | 55.28% | |||
| Normalized Diluted EPS | 4.29% | 55.28% | |||
| Average Basic Shares Outstanding | 15.65% | 5.96% | |||
| Average Diluted Shares Outstanding | 15.65% | 5.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||